Menu Search
Equities

Genincode PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9PL:STU

Genincode PLC

Actions
  • Price (EUR)0.0005
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-98.85%
  • Beta2.4135
Data delayed at least 15 minutes, as of Feb 09 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.

  • Revenue in GBP (TTM)2.91m
  • Net income in GBP-4.97m
  • Incorporated2018
  • Employees36.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.